Eli Lilly Says FDA Approves Inluriyo in Combination With Verzenio for Breast Cancer

02:36 PM EDT, 09/18/2026 (MT Newswires) -- Eli Lilly (LLY) said Friday that the US Food and Drug Administration has approved Inluriyo in combination with Verzenio for breast cancer. The approval covers adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease has progressed following at least one line of endocrine therapy. The approval is based on clinical benefit observed in the phase 3 Ember-3 trial with Inluriyo in combination with Verzenio at clinical progression. Inluriyo and Verzenio target two different drivers of tumor growth, offering a combined approach to help slow the disease. The combination is now available in the US, according to the company. Price: 1148.84, Change: -3.60, Percent Change: -0.31